[Dilip Davda] APL is engaged in the marketing and manufacturing of pharma products. It is largely operating on a B2B model. Spurt in its bottom lines from FY24 raise eyebrows and concern over its sustainability. It does contract manufacturing business that has large volume but less margins. Based on its financial data, the issue appears aggressively priced. Well-informed investors may park funds for long term. Read detail review...

Accretion Pharmaceuticals IPO Peer Comparison

Accretion Pharmaceuticals Limited peer comparison with similar listed entities. (As on March 28, 2024)

Company Name	EPS (Basic)	EPS (Diluted)	NAV (per share) (Rs)	P/E (x)	RoNW (%)	P/BV Ratio	Financial statements
Accretion Pharmaceuticals Limited	8.74	8.74	17.09	11.56	38.54	5.94	Standalone
Sakar Healthcare Limited	5.64	5.64	120.65	48.89	4.45		Standalone
Lincoln Pharmaceuticals Ltd.	46.58	46.58	295.98	12.30	15.74	1.98	Standalone
Sotac Pharmaceuticals Limited	5.24	5.24	43.69	23.85	11.91		Standalone

Source: The Company's Financial Figures are based on restated standalone audited financial statements for the period ended on July 20, 2024 unless provided otherwise. Concerning Industry peers, all the financial information mentioned above is on a standalone basis. It is sourced from the audited results of the respective companies for the year ended March 31, 2024 unless provided otherwise.

Notes for peer group:

The P/E Ratio has been computed based on the closing market price of equity shares on the NSE on May 05, 2025 (except for Sotac Pharmaceuticals Limited, which is taken as on April 24, 2025) divided by the Basic EPS as at March 31, 2024.
Return on Net Worth (%) = net profit after tax divided by net worth. Net worth has been computed as the aggregate of share capital and reserves and surplus/Other Equity as on March 31, 2024.
NAV is computed as the closing net worth as on March 31, 2024, divided by the outstanding number of equity shares as on March 31, 2024.

Accretion Pharmaceuticals IPO Review by Members

Accretion Pharmaceuticals IPO Reviews, analysis and views by popular members. Read Accretion Pharmaceuticals Ltd. IPO reviews by retail investors to find recommended ipo to buy.

Accretion Pharmaceuticals IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid
Count	0	0	0	0
%	0.00	0.00	0.00	0.00

Member	Review
No recommendation found. Be the first to post the recommendation.

Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.

Accretion Pharmaceuticals IPO Review & Recommendations

Accretion Pharmaceuticals IPO Review Summary from brokers and analysts

Accretion Pharmaceuticals IPO Review by Dilip Davda May apply

Accretion Pharmaceuticals IPO Peer Comparison

Accretion Pharmaceuticals IPO Review by Members

Accretion Pharmaceuticals IPO Review Summary by Members

Read more about Accretion Pharmaceuticals IPO